|
| Fig. 50.3 Cutaneous atrophy and slight hypopigmentation from
intralesional corticosteroids. (Courtesy of the Fitzsimons Army Medical
Center teaching files.) |
|
| Fig. 50.4 Striae associated with midpotency topical steroid use. |
Within 1 to 3 weeks of using superpotent topical
steroids, the dermal volume is measurably reduced.
This is due to decreased fibroblast production of
dermal ground substance, primarily hyaluronic acid,
and decreased dermal water content. Abnormal
synthesis of collagen and elastin results in dermal
atrophy (Fig. 50-3), skin fragility, striae (Fig. 50-4),
telangiectasias, poor vascular support with skin
purpura, and decreased wound healing.